====== Sarah Buchan ======

{{ ::sarah-buchan-180x180.jpeg?200|}}

Dr. **Sarah Buchan** is a Canadian epidemiologist and specialist in vaccine-preventable diseases based in [[canada:Ontario:Toronto]], [[canada:Ontario]].

===== Education =====

  * PhD, Epidemiology, [[Dalla Lana School of Public Health]], [[University of Toronto]]
  * MSc, Global Health and Development, [[University College London]]
  * BScH, Biology, [[Queen's University]]

===== Career and Affiliations =====

==== Public Health Ontario ====

Buchan is a scientist at [[Public Health Ontario]] (PHO) in Health Protection where she conducts applied public health research related to the [[epidemiology]] of vaccine-preventable and other [[infectious diseases]].((//Dr. Sarah Buchan.// (2021, September 10). Public Health Ontario. https://archive.ph/H0PNH))
She has been supporting PHO’s COVID-19 Incident Management System since February 2020, with a focus on addressing questions to support the provincial response and inform decision-making. She has also contributed to analyses related to COVID-19 burden, transmission, variants of concern, immunization, and vaccine effectiveness.((//Occupational and Environmental Health Seminar: “Exploring COVID-19 cases and outbreaks by industry.”// (2022, February 24). Dalla Lana School of Public Health. https://archive.ph/PrWGb))

==== University of Toronto ====

Buchan is an assistant professor at the [[Dalla Lana School of Public Health]] and the [[Institute for Pandemics]] at the [[University of Toronto]].((//Buchan, Sarah A.// Dalla Lana School of Public Health. Retrieved May 11, 2022, from https://archive.ph/BoXgQ)) ((//Sarah Buchan.// Institute for Pandemics. Retrieved May 12, 2022, from https://archive.ph/8GPdK))

==== ICES ====

Buchan is an adjunct scientist at the [[Institute for Clinical Evaluative Sciences]] (ICES).((//Sarah Buchan.// ICES. Retrieved May 12, 2022, from https://archive.ph/jX5By))

==== Ontario COVID-19 Science Advisory Table ====

Buchan is a member of the Modelling Consensus Table of the [[Ontario COVID-19 Science Advisory Table]].((//Our Partners.// Ontario COVID-19 Science Advisory Table. Retrieved May 9, 2022, from https://web.archive.org/web/20220509143427/https://covid19-sciencetable.ca/our-partners/))

===== Research =====

Buchan's work around 2016 was supported by a [[Canadian Immunization Research Network]] Trainee Award, including a study of [[influenza vaccines]] and [[vaccine hesitancy]].((Buchan, S. A., & Kwong, J. C. (2016). //Trends in influenza vaccine coverage and vaccine hesitancy in Canada, 2006/07 to 2013/14: results from cross-sectional survey data.// CMAJ Open, 4(3), E455–E462. https://doi.org/10.9778/cmajo.20160050))

==== Areas of Focus ====

  * Immunization
  * [[Infectious diseases]]
  * Pediatric health
  * Health services research

==== RSV ====

In 2018, Buchan co-authored a paper on [[RSV]] funded by the [[Center for disease control and prevention|U.S. Centers for Disease Control and Prevention]] (CDC) through their Achieving Public Health Impact through Research program.((Regan, A. K., Klein, N. P., Langley, G., Drews, S. J., Buchan, S., Ball, S., Kwong, J. C., Naleway, A., Thompson, M., Wyant, B. E., Levy, A., Chung, H., Feldman, B., Katz, M. A., Azziz-Baumgartner, E., Shifflet, P., Fink, R. V., Fell, D., Riesel, D., & Mandelboim, M. (2018). //Respiratory Syncytial Virus Hospitalization During Pregnancy in 4 High-income Countries, 2010–2016.// Clinical Infectious Diseases, 67(12), 1915–1918. https://doi.org/10.1093/cid/ciy439))

She's also received funding from [[SickKids]].((Buchan, S. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220509143509/https://covid19-sciencetable.ca/wp-content/uploads/2020/10/Declaration-of-Interest_Modeling-Consensus-Table_Sarah-Buchan.pdf))
==== Influenza ====

Buchan received a $202,725 grant from ICESs in 2018 for a project titled //"Influenza vaccines, statins, and laboratory-confirmed influenza outcomes in older adults: can vaccines and statins reduce the burden of influenza?"//((//Sarah Buchan.// ICES. Retrieved May 12, 2022, from https://archive.ph/jX5By))

==== COVID-19 ====

Buchan published a study examining adverse events related to [[COVID-19 vaccines]], funded by the [[Canadian Immunization Research Network]] (CIRN), [[Public Health Agency of Canada]] and the [[Canadian Institutes of Health Research]] (CIHR).((Nasreen, S., Calzavara, A., Buchan, S. A., Thampi, N., Johnson, C., Wilson, S. E., & Kwong, J. C. (2022).// Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.// Vaccine. https://doi.org/10.1016/j.vaccine.2022.04.065))

Previously, she co-authored a study titled //"Effectiveness of [[BNT162b2]] and [[mRNA-1273]] [[covid-19 vaccines]] against symptomatic [[SARS-CoV-2]] infection and severe [[covid-19]] outcomes in Ontario, Canada: test negative design study"//.((Chung, H., He, S., Nasreen, S., Sundaram, M. E., Buchan, S. A., Wilson, S. E., Chen, B., Calzavara, A., Fell, D. B., Austin, P. C., Wilson, K., Schwartz, K. L., Brown, K. A., Gubbay, J. B., Basta, N. E., Mahmud, S. M., Righolt, C. H., Svenson, L. W., MacDonald, S. E., & Janjua, N. Z. (2021). //Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.// BMJ (Clinical Research Ed.), 374, n1943. https://doi.org/10.1136/bmj.n1943)) This also received funding from the CIRN, PHAC and CIHR, as well as the Vaccine Surveillance Reference group and the [[COVID-19 Immunity Task Force]], and the [[Ontario Health Data Platform]].

She also contributed to a study on treatments for [[COVID-19]], funded by the COVID-19 Emergency Response Fund from the [[Ottawa Hospital]].((MacFadden, D. R., Brown, K., Buchan, S. A., Chung, H., Kozak, R., Kwong, J. C., Manuel, D., Mubareka, S., & Daneman, N. (2022). //Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications.// Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofac156))